BenzingaAugust 26, 2026 at 10:24 PM NY8 days ago
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill51 minutes ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 hours ago
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo2 hours ago